CAS 156918-17-1 | CT-2584-004 : CT-2584
(World's Largest Pharmaceutical Supplier)
- CAS Number: 156918-17-1
- Stock: 999g
- Assay: 0.00%
CAS 156918-17-1, also known as rosiglitazone, is a medication used in the treatment of type 2 diabetes. It belongs to a class of drugs called thiazolidinediones, which work by increasing the sensitivity of the body's cells to insulin, thus lowering blood sugar levels.
Rosiglitazone was first approved for use by the United States Food and Drug Administration (FDA) in 1999, and has since become widely prescribed. It is typically taken orally once or twice a day, either alone or in combination with other diabetes medications.
In addition to its primary use in treating diabetes, rosiglitazone has been investigated for its potential use in treating other conditions. For example, some studies have suggested that it may be beneficial in treating polycystic ovary syndrome, a hormonal disorder that can cause infertility and other health problems.
Like all medications, rosiglitazone can cause side effects. Some common side effects include weight gain, edema (swelling), and headaches. In rare cases, it may also increase the risk of heart attack or stroke, particularly in patients with a history of cardiovascular disease.
Due to these potential risks, the use of rosiglitazone has been restricted in certain countries. In the United States, the FDA requires that the drug carry a warning about the potential risk of cardiovascular events, and recommends that it only be used in patients who have not responded to other diabetes medications.
Despite its potential risks, rosiglitazone has been shown to be an effective treatment for type 2 diabetes, helping to improve blood sugar control and reduce the risk of complications associated with the disease. As such, it remains an important tool in the management of this chronic condition, and continues to be an area of active research and development.